A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension

Pulmonary arterial hypertension (PAH) is a rare but fatal disease. Current treatments increase life expectancy but have limited impact on the progressive pulmonary vascular remodelling that drives PAH. Osteoprotegerin (OPG) is increased within serum and lesions of patients with idiopathic PAH and is...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Commun
Main Authors: Arnold, Nadine D., Pickworth, Josephine A., West, Laura E., Dawson, Sarah, Carvalho, Joana A., Casbolt, Helen, Braithwaite, Adam T., Iremonger, James, Renshall, Lewis, Germaschewski, Volker, McCourt, Matthew, Bland-Ward, Philip, Kowash, Hager, Hameed, Abdul G., Rothman, Alexander M. K., Frid, Maria G., Roger Thompson, A. A., Evans, Holly R., Southwood, Mark, Morrell, Nicholas W., Crossman, David C., Whyte, Moira K. B., Stenmark, Kurt R., Newman, Christopher M., Kiely, David G., Francis, Sheila E., Lawrie, Allan
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6858314/
https://ncbi.nlm.nih.gov/pubmed/31729368
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-019-13139-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados